Trump Signs Executive Order to Accelerate Psychedelic Drug Research and Access

1-Minute Brief

The executive order is intended to expand research and access to psychedelics for mental health treatments, including for veterans.

Key Facts

• President Donald Trump signed an executive order aimed at expediting research and access to psychedelic therapies.
• The order seeks to speed up the regulatory process for psychedelic drugs targeting mental illnesses.
• Shares of psychedelic drug companies, such as Compass Pathways and AtaiBeckley, surged following the announcement.
• The order directs the FDA to accelerate clinical trials and 'Right to Try' access for drugs like psilocybin, MDMA, and ibogaine.
• FDA Commissioner Dr. Marty Makary described the move as a 'historic moment' for psychedelic research.

What Happened

President Trump signed an executive order directing federal agencies to expedite research, clinical trials, and access to psychedelic drugs for mental health treatment. The move led to a significant rally in psychedelic drug company stocks.

Why It Matters

The order could increase treatment options for mental health conditions, particularly for veterans, and potentially reshape the regulatory landscape for psychedelic therapies in the U.S.

What's Next

Federal agencies, including the FDA, are expected to implement new guidelines for faster review and expanded access to psychedelic drugs. Industry and advocacy groups will monitor the rollout and its impact on future drug approvals.